Harel Dahari, PhD | Loyola Medicine

Coronavirus 2019 (COVID-19) Update

Loyola Medicine hospitals are prepared to provide appropriate care for the safety and well-being of our community. Learn more here.

Harel Dahari, PhD

Harel Dahari, PhD

Medicine

Hepatology
Associate Professor

Languages Spoken

English, Hebrew

Clinical Expertise

Biography

Interests
Movies

Medical Education

Medical School
Residency
Fellowship

Board Certification

Research

  • Accounting for Space—Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models. Kumberger, P; Durso-Cain, K; Uprichard, SL; Dahari, H; Graw, F, Viruses
  • Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics Ishida, Y.; Chung, T. L.; Imamura, M.; Hiraga, N.; Sen, S.; Yokomichi, H.; Tateno, C.; Canini, L.; Perelson, A. S.; Uprichard, S. L.; Dahari, H.; Chayama, K., Hepatology (Baltimore, Md.)
  • High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members Boodram, B.; Hotton, A. L.; Shekhtman, L.; Gutfraind, A.; Dahari, H., Journal of urban health : bulletin of the New York Academy of Medicine
View All ResearchShow Less
  • How to eliminate HCV in people who inject drugs in the USA Dahari, H.; Boodram, B., The Lancet.Infectious diseases
  • Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users. Major, M; Gutfraind, A; Shekhtman, L; Cui, Q; Kachko, A; Cotler, SJ; Hajarizadeh, B; Sacks-Davis, R; Page, K; Boodram, B; Dahari, H, Science translational medicine
  • Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics Reinharz, V.; Dahari, H.; Barash, D., Mathematical biosciences
  • End of treatment RNA-positive/sustained viral response in an individual with acute hepatitis C virus infection treated with direct-acting antivirals Shteyer, E.; Dahari, H.; Gafanovich, I.; Dery, I.; Wolf, D.; Cotler, S. J.; Lurie, Y., Therapeutic advances in gastroenterology
  • HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients Canini, L.; Imamura, M.; Kawakami, Y.; Uprichard, S. L.; Cotler, S. J.; Dahari, H.; Chayama, K., PLoS ONE
  • Modeling HCV cure after an ultra-short duration of therapy with direct acting agents Goyal, A.; Lurie, Y.; Meissner, E. G.; Major, M.; Sansone, N.; Uprichard, S. L.; Cotler, S. J.; Dahari, H., Antiviral Research
  • Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection Canini, L.; Koh, C.; Cotler, S. J.; Uprichard, S. L.; Winters, M. A.; Han, M. A. T.; Kleiner, D. E.; Idilman, R.; Yurdaydin, C.; Glenn, J. S.; Heller, T.; Dahari, H., Hepatology communications
  • Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies Malespin, M.; Benyashvili, T.; Uprichard, S. L.; Perelson, A. S.; Dahari, H.; Cotler, S. J., Therapeutic advances in gastroenterology
  • Cure prevents more than transmission of HCV Dahari, H.; Cotler, S. J.; Feld, J. J., Hepatology (Baltimore, Md.)
  • HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir simeprevir or ledipasvir, Dahari, H.; Canini, L.; Graw, F.; Uprichard, S. L.; Araujo, E. S.; Penaranda, G.; Coquet, E.; Chiche, L.; Riso, A.; Renou, C.; Bourliere, M.; Cotler, S. J.; Halfon, P., Journal of Hepatology
  • Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report Hasin, Y.; Shteingart, S.; Dahari, H.; Gafanovich, I.; Floru, S.; Braun, M.; Shlomai, A.; Verstandig, A.; Dery, I.; Uprichard, S. L.; Cotler, S. J.; Lurie, Y., WORLD JOURNAL OF HEPATOLOGY
  • Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy DebRoy, S.; Hiraga, N.; Imamura, M.; Hayes, C. N.; Akamatsu, S.; Canini, L.; Perelson, A. S.; Pohl, R. T.; Persiani, S.; Uprichard, S. L.; Tateno, C.; Dahari, H.; Chayama, K., Journal of viral hepatitis
  • Resurrection of response-guided therapy for sofosbuvir combination therapies Dahari, H.; Halfon, P.; Cotler, S. J., Journal of Hepatology
  • Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections Gutfraind, A.; Boodram, B.; Prachand, N.; Hailegiorgis, A.; Dahari, H.; Major, M. E., PLoS ONE
  • Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago Echevarria, D.; Gutfraind, A.; Boodram, B.; Major, M.; Del Valle, S.; Cotler, S. J.; Dahari, H., PLoS ONE
  • Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised double-blind, placebo-controlled phase 2A trial, Koh, C.; Canini, L.; Dahari, H.; Zhao, X.; Uprichard, S. L.; Haynes-Williams, V.; Winters, M. A.; Subramanya, G.; Cooper, S. L.; Pinto, P.; Wolff, E. F.; Bishop, R.; Ai Thanda Han, M.; Cotler, S. J.; Kleiner, D. E.; Keskin, O.; Idilman, R.; Yurdaydin, C.; Glenn, J. S.; Heller, T., The Lancet.Infectious diseases
  • Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach Graw, F.; Martin, D. N.; Perelson, A. S.; Uprichard, S. L.; Dahari, H., Journal of virology
  • Reply: To PMID 25098971. Guedj, J; Canini, L; Cotler, S; Dahari, H, Hepatology (Baltimore, Md.)
  • Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Canini, L; DebRoy, S; Mariño, Z; Conway, JM; Crespo, G; Navasa, M; D'Amato, M; Ferenci, P; Cotler, SJ; Forns, X; Perelson, AS; Dahari, H, ANTIVIRAL THERAPY
  • Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics Dahari, H.; Shteingart, S.; Gafanovich, I.; Cotler, S. J.; D'Amato, M.; Pohl, R. T.; Weiss, G.; Ashkenazi, Y. J.; Tichler, T.; Goldin, E.; Lurie, Y., Liver international : official journal of the International Association for the Study of the Liver
  • Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C Rotman, Y.; Noureddin, M.; Feld, J. J.; Guedj, J.; Witthaus, M.; Han, H.; Park, Y. J.; Park, S. H.; Heller, T.; Ghany, M. G.; Doo, E.; Koh, C.; Abdalla, A.; Gara, N.; Sarkar, S.; Thomas, E.; Ahlenstiel, G.; Edlich, B.; Titerence, R.; Hogdal, L.; Rehermann, B.; Dahari, H.; Perelson, A. S.; Hoofnagle, J. H.; Liang, T. J., Gut
  • Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach Dahari, H.; Cotler, S. J., Hepatology (Baltimore, Md.)
  • Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. Rong, L; Guedj, J; Dahari, H; Perelson, AS, ANTIVIRAL THERAPY
  • Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling Guedj, J.; Rotman, Y.; Cotler, S. J.; Koh, C.; Schmid, P.; Albrecht, J.; Haynes-Williams, V.; Liang, T. J.; Hoofnagle, J. H.; Heller, T.; Dahari, H., Hepatology (Baltimore, Md.)
  • Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model Rong, L.; Guedj, J.; Dahari, H.; Coffield, D. J., Jr; Levi, M.; Smith, P.; Perelson, A. S., PLoS computational biology
  • Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Guedj, J.; Dahari, H.; Rong, L.; Sansone, N. D.; Nettles, R. E.; Cotler, S. J.; Layden, T. J.; Uprichard, S. L.; Perelson, A. S., Proceedings of the National Academy of Sciences of the United States of America
  • Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection Zhang, J.; Lipton, H. L.; Perelson, A. S.; Dahari, H., Journal of virology
  • Silymarin for HCV infection Polyak, S. J.; Oberlies, N. H.; Pecheur, E. I.; Dahari, H.; Ferenci, P.; Pawlotsky, J. M., ANTIVIRAL THERAPY
  • The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate Guedj, J.; Dahari, H.; Uprichard, S. L.; Perelson, A. S., Expert review of gastroenterology & hepatology
  • Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling Dahari, H.; Cotler, S. J.; Layden, T. J.; Perelson, A. S., Journal of Hepatology
  • The rate of hepatitis C virus infection initiation in vitro is directly related to particle density Sabahi, A.; Marsh, K. A.; Dahari, H.; Corcoran, P.; Lamora, J. M.; Yu, X.; Garry, R. F.; Uprichard, S. L., Virology
  • Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon Dahari, H.; Sainz, B., Jr; Perelson, A. S.; Uprichard, S. L., Journal of virology